SCHEMBL3907479

SCHEMBL3907479

O=C(O)CN1C(=O)C(=Cc2ccc(Br)o2)SC1=S

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.66
▸ MEN1 O00255 4/20 0.66
▸ POLB P06746 4/20 0.66
▸ KMT2A Q03164 4/20 0.66
▸ KDM4E B2RXH2 3/20 0.66
▸ TDP1 Q9NUW8 3/20 0.66
▸ L3MBTL1 Q9Y468 3/20 0.66
▸ ALDH1A1 P00352 3/20 0.64
▸ MAP3K5 Q99683 2/20 0.64
▸ LMNA P02545 2/20 0.64
▸ RECQL P46063 2/20 0.64
▸ USP2 O75604 1/20 0.64
▸ SAE1 Q9UBE0 1/20 0.64
▸ UBA2 Q9UBT2 1/20 0.64
▸ APEX1 P27695 2/20 0.61
▸ PTPN22 Q9Y2R2 2/20 0.60
▸ HPGD P15428 2/20 0.60
▸ HTT P42858 1/20 0.60
▸ GAA P10253 1/20 0.60
▸ PTPN12 Q05209 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3907475 1.00 MAPT (0.66) MAPTMEN1POLBKMT2AKDM4E
SCHEMBL3908236 0.88 MAPT (0.69) MAPTMEN1POLBKMT2AKDM4E
SCHEMBL3908238 0.88 MAPT (0.69) MAPTMEN1POLBKMT2AKDM4E
SCHEMBL10492308 0.84 MAPT (0.66) MAPTMEN1POLBKMT2AKDM4E
SCHEMBL10492310 0.84 MAPT (0.66) MAPTMEN1POLBKMT2AKDM4E
SCHEMBL29754022 0.84 MAPT (0.66) MAPTMEN1POLBKMT2AKDM4E
SCHEMBL8594085 0.84 MAP3K5 (0.78) MAPTMAP3K5APEX1PTPN22
SCHEMBL13056331 0.84 MAP3K5 (0.78) MAPTMAP3K5APEX1PTPN22
SCHEMBL8594082 0.84 MAP3K5 (0.78) MAPTMAP3K5APEX1PTPN22
SCHEMBL13056366 0.82 MAPT (0.79) MAPTMEN1POLBKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US claimed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 — — WO claimed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 MAPT 1187/4885MEN1 1562/4885POLB 2008/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 MAPT 880/4885MEN1 2869/4885POLB 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback